Check out which companies are making headlines before the bell:
Apple – The iPhone maker has signed a long-rumored deal with China Mobile, the world's largest mobile carrier. China Mobile will begin offering Apple's signature smartphone to its customers on January 17.
Target – Traffic at Target stores fell during the last pre-Christmas weekend, in the wake of the massive credit and debit card data breach. The Wall Street Journal said transactions at Target fell 3-4 percent compared with the same weekend a year ago.
Tiffany – The luxury goods retailer cut its outlook for the year, after a Dutch court awarded $449 million in damages to Swatch. The case involved a failed joint venture between the two companies.
Boeing – The company's machinists will vote on a revised contract offer on January 3. The original eight year proposal was rejected by a 2-1 margin back in November, a deal that had been designed to keep production of the 777-X jet in Washington state.
Facebook– The social network priced a secondary offering of 70 million shares at $55.05 per share. About 41.4 million of those shares by chief executive officer Mark Zuckerberg, in order to pay taxes incurred because of exercised options.
Archer Daniels Midland – The grain processor will pay more than $36 million to settle bribery-related charges related to its operations in Germany and Ukraine.
Hologic– Relational Investors has revealed a 7.3 percent stake in the medical equipment maker. Relational has been calling on the company to provide more details on its plans to reduce debt and return cash to shareholders.
KB Home – Citi upgraded the home builder's shares to "neutral" from "sell", based on recovering earnings and the stock's under-performance relative to the S&P 500.
Micron Technology– Bank of America/Merrill Lynch downgraded the chipmaker's stock to "underperform" from "neutral".
– The FDA will allow Ariad to resume marketing of its leukemia drug Iclusig, although to a narrower patient population than it had previously. The company had suspended sales of the pharmaceutical two months ago, after clinical data showed more than one in four patients suffered serious complications.
—By CNBC's Peter Schacknow
Questions? Comments? Email us at marketinsider@cnbc.com